Recently, the Cardiovascular Imaging Professional Committee of the National Expert Committee on Cardiovascular Diseases was officially established. Initiated by experts including Academician Hu Shengshou and with Academician Wang Zhenchang serving as its first Chairman, the committee brings together hundreds of top experts in the field of cardiovascular imaging in China. Its establishment marks a new stage for resource integration and collaborative innovation in this field in China. Sinotau, as a leading domestic enterprise in innovative radiopharmaceuticals, was honored to be selected as an inaugural member unit of the Imaging Committee. This selection reflects the high recognition from a national-level professional academic organization of the company’s R&D strength and innovative contributions in the field of cardiovascular imaging, and it will also motivate us to participate more deeply in national-level industry collaboration and scientific research.

Partial List of the National Cardiovascular Imaging Committee

Coronary Artery Disease (CAD) is the most common type of cardiovascular disease and one of the diseases with the highest mortality rates globally. In China, the number of patients reached 11.5 million in 20241. Against this backdrop, radionuclide myocardial imaging plays a crucial role in the accurate diagnosis, risk stratification, viable myocardium detection, efficacy evaluation, and prognosis assessment of CAD, leveraging its non-invasive advantages, and holds broad market prospects.

Sinotau, deeply engaged in the field of cardiovascular imaging and focusing on unmet clinical needs, has built a leading cardiovascular diagnostic product pipeline driven by original innovation, demonstrating significant advantages in technology R&D, clinical translation, and commercial potential. The core product, XTR003, is the world’s first and only PET tracer for myocardial fatty acid metabolism imaging that has entered the clinical stage, intended for the detection of viable myocardium. It represents a “first-in-class” globally innovative radiopharmaceutical, having completed Phase I and Phase IIa clinical trials. Current data show excellent performance in safety and diagnostic efficacy, potentially filling a clinical gap. Another core product, XTR004, is China’s first PET Myocardial Perfusion Imaging (MPI) tracer to enter the clinical stage. It has completed Phase I and Phase II clinical trials, with its Phase I research results awarded the Best Translational Paper Award – Molecular Imaging Category by the Journal of Nuclear Cardiology, fully validating its scientific significance and clinical potential. It holds the potential to replace traditional SPECT MPI and promises considerable growth prospects.

In the future, we will remain committed to serving the national strategy for cardiovascular disease prevention and treatment. Leveraging the synergistic advantages formed by XTR003 and XTR004, Sinotau will continue to promote the R&D and clinical translation of innovative radiopharmaceuticals, contributing a core driving force to the improvement of cardiovascular disease diagnosis and treatment levels in China and to the building of a “Healthy China.”

1.Source: Industry Report by China Insights Consultancy (CIC).

The New Drug Application for XTR008 in China was accepted by the National Medical Products Administration (NMPA) in April 2025. XTR008 is expected to receive approval for marketing in China in 2026, potentially becoming the first SSTR-targeted Radioligand Therapy approved in China, offering a new treatment choice for Chinese patients with neuroendocrine tumors.
?